A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022): Experience with the Use of Human Recombinant Interferon Gamma in TB Practice

BACKGROUND: In this article, we present the results of a multicenter clinical trial of IFN-γ in patients with drug-susceptible and drug-resistant pulmonary Tuberculosis (TB) in routine clinical practice. OBJECTIVE: This study aimed to confirm the efficacy and safety of IFN-γ administered to patients with TB. METHODS: All patients were diagnosed with TB after being tested by bacterioscopic and molecular genetic methods and had no contraindications to standard chemotherapy. RESULTS: Recombinant human IFN-γ proved high efficacy in multi-center clinical trial in routine TB practice. CONCLUSION: The results show that IFN-γ is efficient and safe in the treatment of pulmonary tuberculosis. Clinical Trial Registration #: NCT06118619.